MedTrace Logo

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

NCT03452592 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2025-04-03

No results posted yet for this study

Summary

This study is conducted to evaluate the efficacy and safety of Alflutinib in locally advanced or metastatic non-small cell lung cancer patients harbouring T790M mutation

Conditions

  • Advanced NSCLC Patients With T790M

Interventions

DRUG

Alflutinib

Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg

Sponsors & Collaborators

  • Allist Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-30
Primary Completion
2021-04-21
Completion
2024-03-14

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03452592 on ClinicalTrials.gov